Dupilumab significantly reduced exacerbations and improved lung function in adults with uncontrolled chronic obstructive pulmonary disease (COPD) and type 2 inflammation, based on data from more than ...

Share on Pinterest GLP-1 and SGLT-2 drugs may be the best treatments for people with type 2 diabetes and COPD. Image credit: Visual Vic/Getty Images. Researchers estimate the number of people globally ...

These improvements — as measured by a significantly lower annualized rate of acute exacerbations, significantly better lung function and quality of life, and significantly less severe symptoms than ...

In the phase 3 BOREAS study of patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation, patients treated with dupilumab experienced fewer COPD exacerbations, improved lung ...

Sanofi and Regeneron are closing in on an FDA approval for Dupixent to treat those with uncontrolled chronic obstructive pulmonary disease with type 2 inflammation. Approximately 300,000 have the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The phase 3 BOREAS trial included adults with ...

Bhatt’s study, "Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts,” was recently published in The New England Journal of Medicine. Bhatt and colleagues conducted a multicenter ...

Chronic obstructive pulmonary disease (COPD) should be considered in patients who present with respiratory symptoms such as dyspnoea, cough, sputum production and a history of risk factors, especially ...

The natriuretic peptides, specifically brain natriuretic peptide (BNP), are the most specific and applicable laboratory tests available to establish fluid overload associated with HF. 9 BNP is ...

"The key finding as a clinician is to recognize that severe COPD patients have heterogeneity in terms of biological processes, which likely explains variable clinical courses and responses to ...

Chronic obstructive pulmonary disease patients with type 2 inflammation saw rapid and sustained improvements in their disease after treatment with the monoclonal antibody dupilumab, according to a ...